European Regulators Approve Sanofi Meningitis Vaccine for Infants as Young as Six Weeks

Paris, Tuesday, 4 August 2026.
The European Commission expanded approval for Sanofi’s MenQuadfi vaccine to six-week-old infants, broadening early protection against a rapid, severe disease carrying a mortality rate up to 15 percent.